Targeting CDK pathways in cancer treatment

DNA repair inhibitors to overcome drug resistance

Refining the role of PARP inhibitors in targeted anticancer therapy

Developments in immunotherapy

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways

Discovering selective anticancer drugs: succeeding slowly is better than failing fast

Putting adoptive T cell therapy on the path to regulatory approval

Using Hsp90 inhibitors in the clinic: what have we learned?

Radiogenomic evaluation of tumour response to targeted agents

New drugs and targets in haematological malignancies

Mutant-specific kinase inhibitors and TAT highlights

Drugging the cancer genome to overcome drug resistance

TAT 2015: Biological underpinnings of targeted therapies and the importance of dialogue and collaboration

TAT 2015: Cutting edge research and unique interaction between academia and industry

TAT 2015: Exciting new data on immunotherapy, biomarkers, response evaluation and more